<DOC>
	<DOCNO>NCT01874431</DOCNO>
	<brief_summary>To assess new drug , BAY94-8862 give orally different dos , evaluate whether safe help well patient type 2 diabetes diabetic nephropathy . These treatment dos compare placebo .</brief_summary>
	<brief_title>Safety Efficacy Different Oral Doses BAY94-8862 Subjects With Type 2 Diabetes Mellitus Clinical Diagnosis Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Men woman age 18 year older.The low age limit may higher legally require participate country Women childbearing potential include study pregnancy test negative agree use adequate contraception sexually active . Subjects type 2 diabetes mellitus fulfil least 1 follow criterion oral antidiabetic / insulin , document fast glucose &gt; /= 7.0 mmol/L medical history , 2 hour plasma glucose &gt; /=11.1 mmol/L oral glucose tolerance test medical history , glycated hemoglobin ( HbA1c ) &gt; /=6.5 % [ National Glycohemoglobin Standardization Program ( NGSP ) / Diabetes Control Complications Trial ( DCCT ) ] medical history runin visit Subjects clinical diagnosis diabetic nephropathy ( DN ) base least 1 follow criterion : Persistent high albuminuria define urinary albumintocreatine ratio ( UACR ) &gt; /=300 mg/g ( &gt; /= 34 mg/mmol ) 2 3 first morning void sample estimate glomerular filtration rate ( eGFR ) &gt; /=30 mL/min/1.73 m² &lt; 90 mL/min/1.73m² ( Chronic Kidney Disease Epidemiology Collaboration , CKD EPI ) ( mL = milliliter ; min = minute ; m2 = square meter ; g = gram ; mmol = millimole ) Persistent high albuminuria define UACR &gt; /=30 mg/g &lt; 300 mg/g ( &gt; /=3.4mg/mmol &lt; 34 mg/mmol ) 2 3 first morning void sample eGFR &gt; /=30 mL/min/1.73 m² &lt; 90 mL/min/1.73m² Subjects treat angiotensinconverting enzyme inhibitor ( ACEI ) and/or angiotensin receptor blocker ( ARB ) least 3 month without adjustment therapy least 4 week prior screen visit Serum potassium &lt; /= 4.8 mmol/L runin visit screen visit Nondiabetic renal disease Glycated hemoglobin ( HbA1c ) &gt; 12 % runin visit screen visit UACR &gt; 3000 mg/g ( 339mg/mmol ) urinary first morning void sample runin visit screen visit Hypertension mean sit systolic blood pressure ( SBP ) &gt; /=180 mmHg mean sit diastolic blood pressure ( DBP ) &gt; /=110 mmHg runin visit mean supine SBP &gt; /=160 mmHg mean sit DBP &gt; /=100 mmHg screen visit Subjects clinical diagnosis heart failure reduce ejection fraction ( HFrEF ) persistent symptom ( New York Heart Association class IIIV ) runin visit Concomitant therapy eplerenone , spironolactone , renin inhibitor , potassiumsparing diuretic Dialysis acute renal failure within previous 6 month prior runin visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>